D2OC34.SA Doximity, Inc.
- Market cap
- BRL 5.58B
- P/E
- 7.0x
- P/B
- 1.08x
- ROE
- 10.6%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 1 quarter up to Jun 2026.
Is D2OC34.SA undervalued?
Graham numberD2OC34.SA trades 42.2% below its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Doximity, Inc. fundamental analysis
No fundamental analysis for Doximity, Inc. yet.
Doximity, Inc. stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Doximity, Inc.
Doximity, Inc. operates a digital platform for medical professionals in the United States. Its Doximity platform includes a personalized newsfeed that presents clinical and professional content to members, which offers medical articles, clinical trials or research results in an easy-to-consume video format, professional updates and accomplishments of their peers and colleagues, clinical discussions, Op-Med articles for publication, and sponsored content from pharmaceutical m…
Full company profileDoximity, Inc. financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 1 quarter up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Doximity, Inc. annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2023 | 2024 | 2025 | 2026 | 2026 Anlz |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | 419M | 475M | 570M | 645M | 626M |
| Gross Profit | 366M | 425M | 515M | 575M | 532M |
| Operating Income | 125M | 164M | 228M | 215M | 135M |
| EBITDA | 135M | 182M | 241M | 229M | 152M |
| Net Income | 113M | 148M | 223M | 196M | 97.3M |
| EPS | 0.58 | 0.79 | 1.18 | 1.07 | 0.54 |
| Balance Sheet | |||||
| Total Assets | 1.14B | 1.08B | 1.26B | 1.12B | 1.08B |
| Total Liabilities | 171M | 178M | 182M | 173M | 168M |
| Shareholders' Equity | 966M | 901M | 1.08B | 951M | 916M |
| Cash & Short-term Investments | 841M | 763M | 916M | 219M | 274M |
| Cash Flow | |||||
| Operating Cash Flow | 180M | 184M | 273M | 326M | 168M |
| Capital Expenditure | 6.18M | 5.80M | 6.53M | 8.96M | 9.54M |
| Free Cash Flow | 173M | 178M | 267M | 317M | 158M |
| Ratios | |||||
| ROE | 11.7% | 16.4% | 20.6% | 20.6% | 10.6% |
| ROA | 9.9% | 13.7% | 17.7% | 17.4% | 9.0% |
| Net Profit Margin | 26.9% | 31.0% | 39.1% | 30.4% | 15.5% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Doximity, Inc. dividends
Doximity, Inc. has not paid dividends in the last 5 fiscal years.
Who owns Doximity, Inc.
Ownership data of Doximity, Inc. is not available yet.
Doximity, Inc. company profile
- Company name
- Doximity, Inc.
- Ticker
- D2OC34.SA
- Exchange
- Sao Paulo Exchange
- Sector
- Healthcare
- Industry
- Health Information Services
- Employees
- 880
- Fiscal year end
- March
- Address
- 500 3rd Street, San Francisco, CA, United States, 94107
- Phone
- 650 549 4330
- Website
- doximity.com
About Doximity, Inc.
Doximity, Inc. operates a digital platform for medical professionals in the United States. Its Doximity platform includes a personalized newsfeed that presents clinical and professional content to members, which offers medical articles, clinical trials or research results in an easy-to-consume video format, professional updates and accomplishments of their peers and colleagues, clinical discussions, Op-Med articles for publication, and sponsored content from pharmaceutical manufacturers and health systems. The company also offers workflow tools, including Ask, a HIPAA-compliant AI assistant, to access and apply evidence-based medical information within clinical workflows; Scribe, a HIPAA-compliant, AI-powered clinical documentation tool; Telehealth tools for hospitals and health systems; and AMiON, an on-call scheduling tool. The company primarily serves physicians, nurse practitioners, physician assistants, medical students, pharmaceutical manufacturers, and healthcare systems. The company was formerly known as 3MD Communications, Inc. and changed its name to Doximity, Inc. in June 2010. Doximity, Inc. was incorporated in 2010 and is headquartered in San Francisco, California.
Doximity, Inc. management
10- Mr. Jeffrey A. TangneyCo-Founder, CEO & Chairperson · born 1973
- Mr. Siddharth SitaramChief Accounting Officer · born 1978
- Mr. John T. VaughanGeneral Counsel, Corporate Secretary & Chief Compliance Officer · born 1975
- Dr. Steven L. Zatz M.D.President · born 1957
- Mr. Matthew SonefeldtCFO & Principal Financial Officer · born 1980
- Mr. Jey BalachandranChief Technology Officer
- Mr. Perry Scott GoldHead of Investor Relations
- Mr. Bruno MirandaSenior Vice President of Engineering
- Mr. Joel DavisSenior Vice President of Product
- Mr. Ben GreenbergSenior VP & GM Commercial Products